{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:09:32Z","timestamp":1779336572918,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101112","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:12:42Z","timestamp":1769101962000},"page":"101112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer"],"prefix":"10.1016","volume":"46","author":[{"given":"Jesus Edgardo","family":"Hernandez-Hernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9sar Octavio","family":"Lara-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Aranda-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor A.","family":"Dom\u00ednguez-Porras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Moreno-Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"D\u00edaz-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Sof\u00eda","family":"G\u00f3mez-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Villarreal-Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Mohar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101112_bib0001","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctarc.2026.101112_bib0002","doi-asserted-by":"crossref","unstructured":"H.A. Azim, A.H. Partridge, Biology of breast cancer in young women, Breast Cancer Res. 16 (4) (2014) 427, 10.1186\/s13058-014-0427-510.1186\/s13058-014-0427-5.","DOI":"10.1186\/s13058-014-0427-5"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101112_bib0003","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1038\/s41598-025-90053-9","article-title":"Distinct clinicopathological features and treatment differences in breast cancer patients of young age","volume":"15","author":"Humlevik","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101112_bib0004","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","article-title":"Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling","volume":"18","author":"Azim","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101112_bib0005","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101112_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10390","key":"10.1016\/j.ctarc.2026.101112_bib0007","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"The Lancet"},{"issue":"10411","key":"10.1016\/j.ctarc.2026.101112_bib0008","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"The Lancet"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101112_bib0009","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101112_bib0010","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38 (17)","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101112_bib0011","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","article-title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","volume":"22","author":"Denkert","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101112_bib0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10549-023-07079-8","article-title":"Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients","volume":"202","author":"Chen","year":"2023","journal-title":"Breast. Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2026.101112_bib0013","doi-asserted-by":"crossref","first-page":"834651","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 Low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front Mol. Biosci."},{"key":"10.1016\/j.ctarc.2026.101112_bib0014","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JGO.19.00264","article-title":"Young women with breast cancer in Mexico: results of the pilot phase of the Joven & Fuerte prospective cohort","volume":"6","author":"Villarreal-Garza","year":"2020","journal-title":"JCO Glob. Oncol"},{"key":"10.1016\/j.ctarc.2026.101112_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.breast.2016.07.016","article-title":"The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival","volume":"29","author":"Vasconcelos","year":"2016","journal-title":"Breast"},{"issue":"16","key":"10.1016\/j.ctarc.2026.101112_bib0016","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/cncr.35323","article-title":"Characterization of HER2-low breast cancer in young women with germline BRCA1\/2 pathogenetic variants: results of a large international retrospective cohort study","volume":"130","author":"Schettini","year":"2024","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101112_bib0017","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.esmoop.2023.101615","article-title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","volume":"8","author":"Viale","year":"2023","journal-title":"ESMo Open"},{"key":"10.1016\/j.ctarc.2026.101112_bib0018","doi-asserted-by":"crossref","unstructured":"F. Schettini, et al., Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer, NPJ. Breast. Cancer 7 (1) (2021) 1, 10.1038\/s41523-020-00208-2.","DOI":"10.1038\/s41523-020-00208-2"},{"key":"10.1016\/j.ctarc.2026.101112_bib0019","doi-asserted-by":"crossref","unstructured":"H. Lv, et al., Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China, Breast Cancer Res. 27 (1) (2025) 45, 10.1186\/s13058-025-02001-0.","DOI":"10.1186\/s13058-025-02001-0"},{"key":"10.1016\/j.ctarc.2026.101112_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ctarc.2026.101112_bib0021","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101112_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241297079","article-title":"Antibody\u2013drug conjugates in patients with advanced\/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis","volume":"16","author":"Michelon","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ctarc.2026.101112_bib0023","doi-asserted-by":"crossref","unstructured":"D.F. Mendivelso-Gonz\u00e1lez, et al., HER2-low prevalence among Hispanic\/Latino women with breast cancer: a systematic review and meta-analysis, PLoS. One 19 (12) (2024) e0315287, 10.1371\/journal.pone.0315287.","DOI":"10.1371\/journal.pone.0315287"},{"key":"10.1016\/j.ctarc.2026.101112_bib0024","doi-asserted-by":"crossref","unstructured":"T. Akinyemiju, J.X. Moore, A.I. Ojesina, J.W. Waterbor, S.F. Altekruse, Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources, Breast. Cancer Res. Treat. 157 (3)(2016) 575-86, 10.1007\/s10549-016-3840-x 10.1007\/s10549-016-3840-x.","DOI":"10.1007\/s10549-016-3840-x"}],"updated-by":[{"DOI":"10.1016\/j.ctarc.2026.101149","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000}},{"DOI":"10.1016\/j.ctarc.2026.101149","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:56:16Z","timestamp":1770656176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":24,"alternative-id":["S2468294226000213"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101112","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101112"}}